As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

A new proposal in Congress is adding pressure to the embattled industry of pharmacy-benefit managers, or PBMs, middlemen companies with significant influence in the drug supply chain. Bipartisan ...

As the PBM market has become increasingly consolidated ... PBMs have taken advantage of their dominant position in the pharmaceutical supply chain. Today, PBMs operate largely behind the scenes.

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

The association says pharmacy benefit managers (PBM’s) are to blame ... calls them anti-competitive middlemen in the pharmacy supply chain that have been allowed to operate largely unregulated.